Literature DB >> 24090739

Gaucher disease: a diagnostic challenge for internists.

Elena Cassinerio1, Giovanna Graziadei2, Erika Poggiali3.   

Abstract

Gaucher disease (GD), the most common inherited lysosomal storage disorder, is a multiorgan disease due to an autosomal recessive defect of the gene encoding glucocerebrosidase enzyme, responsible for the accumulation of glucosylceramide (glucocerebroside) into reticuloendothelial cells, particularly in the liver, spleen and bone marrow. GD is a clinically heterogeneous disorder and it is conventionally classified in type 1 (non-neuronopathic disease), types 2 and 3 (acute and chronic neuronopathic disease, respectively). Features of clinical presentation and organ involvement as well as age, at presentation are highly variable among affected patients. Splenomegaly and/or thrombocytopenia are the most common presenting features either as incidental findings during routine blood count or physical examination. Other possible clinical manifestations can be hepatomegaly with abnormal liver function tests, bone pain often associated with skeletal complications (pathological fractures, avascular necrosis, osteopenia), pulmonary hypertension and, in neuronopathic forms, neurological manifestations (dysfunction of eye motility, mild mental retardation, behavioural difficulties, choreoathetosis and cramp attacks). For all these reasons GD diagnosis is often a real challenge for internists. In the presence of clinical suspicion of GD, the diagnosis has to be confirmed measuring the betaglucocerebrosidase activity in the peripheral leukocytes and by molecular analysis. Each patient needs an accurate initial multisystemic assessment, staging the damage of all the possible organs involved, and the burden of the disease, followed by regular followup. The correct and early diagnosis permits to treat patients properly, avoiding the complications of the disease.
© 2013.

Entities:  

Keywords:  Chitotriosidase; Gaucher disease; Glucocerebroside; Lysosomial disorders; Rare diseases

Mesh:

Year:  2013        PMID: 24090739     DOI: 10.1016/j.ejim.2013.09.006

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  11 in total

Review 1.  Molecular regulations and therapeutic targets of Gaucher disease.

Authors:  Yuehong Chen; Neetu Sud; Aubryanna Hettinghouse; Chuan-Ju Liu
Journal:  Cytokine Growth Factor Rev       Date:  2018-04-11       Impact factor: 7.638

2.  Tandem mass spectrometry assay of β-glucocerebrosidase activity in dried blood spots eliminates false positives detected in fluorescence assay.

Authors:  Pavlina Wolf; Roy N Alcalay; Christopher Liong; Emmaline Cullen; Michael W Pauciulo; William C Nichols; Ziv Gan-Or; Wendy K Chung; Tina Faulkner; Christopher Bentis; Robert J Pomponio; Xiwen Ma; X Kate Zhang; Joan M Keutzer; Petra Oliva
Journal:  Mol Genet Metab       Date:  2017-10-23       Impact factor: 4.797

3.  Splenomegaly - Diagnostic validity, work-up, and underlying causes.

Authors:  Emelie Curovic Rotbain; Dennis Lund Hansen; Ove Schaffalitzky de Muckadell; Flemming Wibrand; Allan Meldgaard Lund; Henrik Frederiksen
Journal:  PLoS One       Date:  2017-11-14       Impact factor: 3.240

Review 4.  Imaging of non-neuronopathic Gaucher disease: recent advances in quantitative imaging and comprehensive assessment of disease involvement.

Authors:  Andrew J Degnan; Victor M Ho-Fung; Rebecca C Ahrens-Nicklas; Christian A Barrera; Suraj D Serai; Dah-Jyuu Wang; Can Ficicioglu
Journal:  Insights Imaging       Date:  2019-07-10

5.  Presenting signs and patient co-variables in Gaucher disease: outcome of the Gaucher Earlier Diagnosis Consensus (GED-C) Delphi initiative.

Authors:  Atul Mehta; David J Kuter; Sam S Salek; Nadia Belmatoug; Bruno Bembi; Jeremy Bright; Stephan Vom Dahl; Federica Deodato; Maja Di Rocco; Ozlem Göker-Alpan; Derralynn A Hughes; Elena A Lukina; Maciej Machaczka; Eugen Mengel; Aabha Nagral; Kimitoshi Nakamura; Aya Narita; Beatriz Oliveri; Gregory Pastores; Jordi Pérez-López; Uma Ramaswami; Ida V Schwartz; Jeff Szer; Neal J Weinreb; Ari Zimran
Journal:  Intern Med J       Date:  2019-05       Impact factor: 2.048

6.  Screening for Gaucher Disease Using Dried Blood Spot Tests: A Japanese Multicenter, Cross-sectional Survey.

Authors:  Toshihiro Miyamoto; Masaki Iino; Yasuji Komorizono; Toru Kiguchi; Nobufusa Furukawa; Maki Otsuka; Shohei Sawada; Yutaka Okamoto; Kenji Yamauchi; Toshitaka Muto; Tomoaki Fujisaki; Hisashi Tsurumi; Kimitoshi Nakamura
Journal:  Intern Med       Date:  2021-03-01       Impact factor: 1.271

Review 7.  Neurodegenerative Disease Risk in Carriers of Autosomal Recessive Disease.

Authors:  Sophia R L Vieira; Huw R Morris
Journal:  Front Neurol       Date:  2021-06-04       Impact factor: 4.003

8.  Pharmacological chaperone design for reducing risk factor of Parkinson's disease from traditional chinese medicine.

Authors:  Hung-Jin Huang; Cheng-Chun Lee; Calvin Yu-Chian Chen
Journal:  Evid Based Complement Alternat Med       Date:  2014-01-19       Impact factor: 2.629

9.  Gaucher disease in Iraqi children (Clinical, diagnostic & therapeutic aspects).

Authors:  Rabab Farhan Thejeal; Ausama Jamal Kadhum
Journal:  Pak J Med Sci       Date:  2016 Mar-Apr       Impact factor: 1.088

10.  Scoring system to facilitate diagnosis of Gaucher disease.

Authors:  Atul Mehta; Oliver Rivero-Arias; Magy Abdelwahab; Samantha Campbell; Annabel McMillan; Mark J Rolfe; Jeremy R Bright; David J Kuter
Journal:  Intern Med J       Date:  2020-12       Impact factor: 2.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.